NCT03211572View on ClinicalTrials.gov

The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers

PHASE2UnknownINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

August 31, 2017

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Breast Cancer
Interventions
DRUG

Tamoxifen

Participants will take endocrine therapy for 2 weeks prior to surgery.

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER